Therapeutic Management of Unresectable Stage III Non-small Cell Lung Cancer with Durvalumab

01 Oct 2024
Therapeutic Management of Unresectable Stage III Non-small Cell Lung Cancer with Durvalumab
Non-small cell lung cancer (NSCLC) constitutes about 85% of all lung cancer cases.1 Of those diagnosed with NSCLC in Hong Kong, approximately 13% are found to have stage III disease.2 Prior to the advent of immunotherapy, the standard of care (SoC) involved concurrent chemoradiotherapy (cCRT) followed by active surveillance.3 However, outcomes have been poor, with most patients experiencing disease progression after CRT. This has resulted in a 5-year overall survival (OS) rate of 15–30% for stage III NSCLC.4

Resources

Therapeutic Management of Unresectable Stage III Non-small Cell Lung Cancer with Durvalumab

Therapeutic Management of Unresectable Stage III Non-small Cell Lung Cancer with Durvalumab

Therapeutic Management of Unresectable Stage III Non-small Cell Lung Cancer with Durvalumab

Therapeutic Management of Unresectable Stage III Non-small Cell Lung Cancer with Durvalumab